Fund Evaluator:
First Trust NYSE Arca Biotech ETF (FBT)
Follow This Fund
Equity
Global Asset Class
Sector Equity
Fund Group
Health
Category
$123.610
NAV (as of Oct 07)
$0.00
Minimum Initial
0.55% C
Expense Ratio
$2,659 Mil
Assets
Open
Status
0.00%
12b-1 Fee
0.00%
TTM Yield
0.00%
Max Load
37%
Portfolio Turnover
Best Performing in Health Over the Last Year
| 62.8% | Fidelity Advisor Biotechnology Z (FIJYX) |
| 62.6% | Fidelity Advisor Biotechnology I (FBTIX) |
| 56.2% | Eventide Healthcare & Life Sciences N (ETNHX) |
| 53.5% | Fidelity Select Biotechnology (FBIOX) |
| 49.5% | Fidelity Select Pharmaceuticals Port (FPHAX) |
Data as of 7/31/2026
-1.1% D
1-Mo Return
19.7% A
3-Mo Return
19.1% A
YTD Return
49.5% B
1-Yr Return
16.7% A
3-Yr Return
8.0% A
5-Yr Return
0.93 C
Category Risk Index
1.53
Total Risk Index
Fund Details
Fund Family
First Trust
Inception Date
6/19/2006
Share Class Type
Equity Investment Style
Mid-Cap
Blend
Bond Investment Style
na
Socially Responsible Fund
No
Index Fund
Yes
Benchmark Index
S&P 500 (TR) (1970): 100%
Additional Fund Details
First Trust NYSE Arca Biotech ETF Overview
FBT Trailing NAV Total Returns Data as of 7/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| FBT Return (NAV) | -1.1% | 19.7% | 49.5% | 16.7% | 8.0% | 9.4% |
| FBT Grade | D | A | B | A | A | B |
| +/- Category | -0.7% | 9.1% | 15.6% | 6.0% | 3.0% | 0.1% |
| Health Avg | -0.4% | 10.7% | 33.9% | 10.7% | 5.0% | 9.3% |
| FBT Tax Cost Ratio | na | na | 0.0% | 0.1% | 0.1% | 0.0% |
FBT Annual NAV Total ReturnsData as of 7/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| FBT Return (NAV) | 19.1% | 24.1% | 5.7% | 2.3% | -4.6% | -3.6% | 12.9% | 19.8% | -0.2% | 37.0% | -19.6% |
| FBT Grade | A | B | A | C | B | D | F | D | C | A | F |
| +/- Category | 12.0% | 3.5% | 3.2% | -3.3% | 4.8% | -12.4% | -11.5% | -8.6% | -0.6% | 13.6% | -8.7% |
| Health Avg | 7.1% | 20.6% | 2.5% | 5.6% | -9.4% | 8.7% | 24.5% | 28.4% | 0.4% | 23.4% | -10.9% |
| Risk Measures | |
| Standard Deviation: | 18.8% |
| Total Risk Index: | 1.53 - Above Average |
| Category Risk Index: | 0.93 - Average |
| Category Risk Grade: | C (56% Rank) |
| Beta: | 0.77 |
| R-Squared: | 27% |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Mid-Cap Blend |
| Bond Investment Style: | na |
| Yield: | 0.0% |
| Dividend Distribution: | Quarterly |
| Cap Gains Distribution: | Annually |
| Total Assets: | $2659 Mil |
| Fund Total Assets: | $2,660 Mil |
| Share Class Type: | |
| Portfolio Turnover: | 37% |
Management Team
| Number of Managers: 7 | |||
| Longest Tenure: 20.1 years | |||
| Average Tenure: 16.6 years | |||
| Managers (Year): Lindquist Daniel (2006), Erickson Jon (2006), McGarel David (2006), Testin Roger (2006), Ueland Stan (2006), Peterson Chris (2016), Russo Erik (2020) | |||
Portfolio Composition (as of 7/30/26)
| # of Holdings: | 32 |
| % in Top 10 Holdings: | 36.2% |
| Fund is Non-Diversified: | No |
| % in Foreign Issues: | 3.3% |
Portfolio Allocation |
|
| Domestic Stock: | 96.6% |
| Foreign Stock: | 3.3% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.2% |
Purchase Information
| Fund Family: | First Trust |
| Phone Number: | 800-621-1675 |
| Website: | www.ftportfolios.com |
| Status: | Open |
| Inception Date: | June 19, 2006 |
| Min. Initial Purchase: | $ 0 |
| Min. Initial IRA Purchase: | $ 0 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | 0.00% |
Expenses and Fees | |
| Expense Ratio (%): | 0.55% ( Rating : Avg ) |
| Category Average Expense Ratio (%): | 1.21% |
| Share Class: | First Trust NYSE Arca Biotech ETF |
| Min. Subsequent Purchase: | $ 0 |
| Min. Subsequent IRA Purchase: | $ 0 |
Copyright 2026 American Association of Individual Investors and Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.